ERBB2 and gastric cancer: Attraction 4, Checkmate 649, and Orient 16 have demonstrated a synergistic effect of immune checkpoint inhibitors (ICIs) in combination with chemotherapy in patients with HER-2 negative, unresectable advanced or recurrent GC/GEJC (7–9).